RhoVac AB: RhoVac's rights issue heavily oversubscribed - subscribed to 196 percent
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.
On 1 June 2018, the subscription period ended in the rights issue in RhoVac AB (publ) (“RhoVac” or “the Company”), which was made public on the 9 April 2018. The result shows that 1,159,045 shares, corresponding to 85.2 percent of the offered shares where subscribed for with subscription rights. In addition, subscriptions corresponding to 1,513,788 shares have been received without subscription rights. The rights issue was consequently oversubscribed by 96.5 percent and will provide the Company with approximately 24.5 MSEK before issue costs, estimated to approximately 3.3 MSEK.
Those who have subscribed for shares without the support of subscription rights will be allotted shares in accordance with the principles stated in the memorandum. Notice of the allotment of shares subscribed for without subscription rights will be sent out within shortly to those who have been allotted shares. Payment shall be done in accordance with the instructions on the settlement note.
Through the rights issue the Company’s share capital will increase with 244,891.26 SEK from 1,469,347.92 SEK to 1,714,239.18 SEK and the number of shares will increase with 1,360,507 from 8,163,044 to 9,523,551. Paid subscribed shares (BTAs) will be converted into new shares as soon as the rights issue has been registered with the Swedish Companies Registration Office. Until then, trading in BTA will continue on Spotlight Stock Market.
Arctic Securities AS, Sweden branch, is acting as financial adviser to RhoVac in connection with the rights issue. Advokatfirman Lindahl is acting as legal adviser to the Company.For more information, please contact: Anders Ljungqvist - VD, RhoVac AB Phone: +45 4083 2365 E-mail: email@example.com This is an English version of an original Swedish press release communicated by RhoVac AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that RhoVac AB is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person, at 9:00 on the 7 June 2018. Important information The information in this press release does not constitute an offer to acquire, subscribe for, or otherwise trade in RhoVac AB shares or other securities. No action has or will be taken by RhoVac to allow an offer to the public in jurisdictions other than Sweden. The information in this press release may not be released, published, reproduced, or distributed in or into the United States or other country or jurisdiction in which such action is not permitted, or in which such action is subject to legal restrictions or would require further registration or actions other than what follows from Swedish law. Failure to comply with these instructions may result in a violation of applicable securities legislation. No shares have or will be registered under the United States Securities Act of 1933, as amended, (the "Securities Act") and may not be offered, subscribed for, sold, or transferred, directly or indirectly, within the United States, except after written approval from RhoVac and under an applicable exemption from the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States. Forward-looking statements This press release contains certain forward-looking statements that reflect the Company's current view and expectations of future events and financial and operational development, including statements regarding the Issue as well as statements regarding guidance, planning, prospects, and strategies. Words such as "intend", "expect", "plan", "anticipate", "estimate", "may", and other expressions that imply indications or predictions of future development or trends, and which are not based on historical facts, constitute forward-looking statements. Although the Company considers these statements to be based on reasonable assumptions and expectations, the Company cannot guarantee the realisation of such forward-looking statements. As these forward-looking statements involve both known and unknown risks and uncertainties, the actual outcome may differ materially from the forward-looking statements. The forward-looking statements in the press release speak only as of its date and are subject to change without notice. The Company makes no commitment to publish updates or revisions of forward-looking statements as a result of new information, future events, or the like, beyond what is required by applicable laws or stock market regulations.About RhoVac AB RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Stock Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com
"RhoVac utvecklar ett immunterapeutiskt läkemedel för behandling av metastaserande cancer. Läkemedlet samarbetar med kroppens immunförsvar och är riktat mot proteinet RhoC som är överuttryckt i alla metastaserande cancerceller."Medicon Village, Scheelevägen 2,
223 81 LUND +45 4083 2365 http://www.rhovac.com